Roth MKM initiated coverage of Replimune with a Buy rating and $17 price target. The analyst believes RP1 will get accelerated approval for anti-PD1 failed melanoma and have a successful launch in late 2025. The firm also sees longer term follow-up of RP1 in first-line cutaneous squamous cell carcinoma next year as a share :repricing opportunity.” Beyond RP1, there is potential for RP2 to succeed in metastatic uveal melanoma, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Replimune announces first patient dosed in IGNYTE-3 trial
- Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
- Replimune Group price target lowered to $14 from $17 at JPMorgan
- Replimune Group initiated with a Buy at Rodman & Renshaw
- Replimune Group files to sell 11.34M shares of common stock for holders
Questions or Comments about the article? Write to editor@tipranks.com